Banno, Koji

写真a

Affiliation

School of Medicine, Department of Obstetrics and Gynecology (Gynecology) (Shinanomachi)

Position

Associate Professor

E-mail Address

E-mail address

External Links

Career 【 Display / hide

  • 1992.05
    -
    1993.05

    慶應義塾大学病院研修医

  • 1995.07
    -
    1996.03

    慶應義塾大学助手(医学部産婦人科学)

  • 1996.04
    -
    2000.03

    癌研究会癌研究所細胞生物部研究生

  • 2001.06
    -
    2005.03

    慶應義塾大学助手(医学部産婦人科学)

  • 2005.04
    -
    2007.03

    慶應義塾大学助手(医学部産婦人科学・外来医長)

display all >>

Academic Background 【 Display / hide

  • 1992

    Keio University, Faculty of Medicine

    University, Graduated

  • 2000

    Keio University, Graduate School, Division of Medicine, 婦人科腫瘍学・細胞生物学

    Graduate School, Completed, Doctoral course

Academic Degrees 【 Display / hide

  • 博士(医学), Keio University, Coursework

Licenses and Qualifications 【 Display / hide

  • 日本婦人科腫瘍学会指導医

  • 日本臨床細胞学会専門医

  • がん治療認定医

  • 日本臨床細胞学会 指導医

  • 日本婦人科腫瘍学会 専門医

display all >>

 

Research Areas 【 Display / hide

  • Human genetics

  • Obstetrics and gynecology

Research Keywords 【 Display / hide

  • エピジェネテイクス

  • 子宮体癌

  • 子宮内膜

  • 子宮移植

  • 家族性腫瘍

 

Books 【 Display / hide

  • 婦人科腫瘍治療アップデート.

    安達将隆、阪埜浩司、青木大輔., 中外医学社, 2020.09

    Scope: Lynch症候群,  Contact page: 220−231

  • Nonhuman Primate Research in Uterus Transplantation.

    Kisu I, Banno K, Matoba Y, Aoki D. , Splinger, 2020.01

    Scope: Nonhuman Primate Research in Uterus Transplantation.,  Contact page: 57-67

  • Cell Biology of the Ovary, Stem Cells, Development, Cancer, and Clinical Aspects

    Kobayashi Y, Nomura H, Kataoka F, Tominaga E, Banno K, Aoki D, USA: Springer, 2018.05

    Scope: Clinical Management of Epithelial Ovarian Cancer.

  • 実践 臨床生殖免疫学

    BANNO KOUJI, 中外医学社, 2018.05

    Scope: 子宮移植

  • 臨床医とための最新産科婦人科

    BANNO KOUJI, 先端医療技術研究所, 2017.08

    Scope: 子宮移植の現状と展望.

display all >>

Papers 【 Display / hide

  • MicroRNA-34b expression enhances chemosensitivity of endometrial cancer cells to paclitaxel

    Yanokura M., Banno K., Aoki D.

    International Journal of Oncology (International Journal of Oncology)  57 ( 5 ) 1145 - 1156 2020.11

    ISSN  10196439

     View Summary

    © 2020 Spandidos Publications. All rights reserved. Aberrant DNA methylation is widely observed in various types of cancer, and expression of microRNAs (miRNAs/miRs) is suppressed by DNA methylation. The present study explored tumor suppressor miRNAs downregulated by DNA methylation in endometrial cancer cells, as the basis of a novel therapeutic approach for endometrial cancer. Among 821 candidate miRNAs, miR-34b was identified as an upregulated miRNA after demethylation treatment in all four endometrial cancer cell lines (HEC-108, SNG-II, Ishikawa and HHUA) examined. miR-34b expression with or without demethylation treatment in cancer cells was confirmed by TaqMan quantitative PCR. MYC and MET, the predicted target genes of miR-34b, were downregulated at both the RNA and protein levels following miR-34b overexpression. Following miR-34b treatment, inhibition of cell growth and invasion, and cell cycle arrest were observed in HEC-108 cells. Sensitivity to paclitaxel was increased in cancer cells with miR-34b overexpression, compared with untreated cancer cells, but this difference was not identified for cisplatin or doxorubicin. In vivo, combination treatment with miR-34b and paclitaxel markedly reduced tumor growth compared with treatment with negative control miRNA and paclitaxel. These data suggest that miR-34b enhances paclitaxel sensitivity in endometrial cancer cells, and that miR-34b and MET are key targets for treatment of endometrial cancer. The present results may contribute to the development of combination treatment with a demethylation agent, miR-34b mimic or MET inhibitor and an anticancer drug.

  • Retrospective evaluation of risk-reducing salphingo-oophorectomy for BRCA1/2 pathogenic variant carriers among a cohort study in a single institution.

    Kobayashi Y, Hirasawa A, Chiyoda T, Ueki A, Masuda K, Misu K, Kowaida M, Hayashi S, Kataoka F, Banno K, Kosaki K, Aoki D.

    Japanese Journal of Clinical Oncology   2020.10

    Research paper (scientific journal), Joint Work, Accepted

  • Evaluation of safety and diagnostic performance for flexible hysteroscopy in 1591 outpatient cases.

    Kobayashi Y, Tsuji K, Nakamura K, Nagai S, Takahashi T, Kobayashi A, Anko M, Hirano T, Watanabe K, Matoba Y, Kunitomi H, Adachi M, Yamagami W, Tominaga E, Banno K, Aoki D.

    Japanese Journal of Clinical Oncology 50 ( 10 ) 1157 - 1161 2020.09

    Research paper (scientific journal), Joint Work, Accepted

     View Summary

    © The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com. BACKGROUND: To date, only few large studies are available concerning the safety and diagnostic concordance rates of outpatient flexible hysteroscopy. In our institution, outpatient hysteroscopy has been routinely and educationally applied Kosuke Tsuji to intrauterine lesions; thus, we retrospectively investigated the institution's outpatient flexible hysteroscopy cases. METHODS: A total of 1591 cases of outpatient flexible hysteroscopy conducted at our institution in 2012-2016 were retrospectively analyzed in terms of their clinical background, complications and diagnostic concordance rates. RESULTS: A total of 1591 cases included 546 cases of benign tumors (317 endometrial polyps, 168 myomas and 61 endometrial hyperplasia), 361 cases of atypical endometrial hyperplasia, 571 cases of endometrial cancers and 113 cases of other diagnoses. No major complications, including uterine perforation, occurred. However, one patient (0.06%) was diagnosed with septic shock caused by intrauterine infection that required prolonged immunosuppressive drug administration. Meanwhile, 335 patients diagnosed with benign tumors through outpatient flexible hysteroscopy underwent operation, and the diagnostic concordance rate was 74.6% (250 cases). However, this rate included 14 cases (4.2%) diagnosed with malignant tumors postoperatively. In preoperative endometrial cancer cases, the sensitivity and specificity for cervical invasion diagnosis were 39.4 and 90.8%, respectively. In addition, only one patient manifested positive ascites cytology intraoperatively, possibly caused by outpatient hysteroscopy. CONCLUSIONS: Outpatient flexible hysteroscopy is highly safe, with a slight negligible effect on ascites cytology. However, the diagnosis should be determined by multidisciplinary approaches, as hysteroscopy alone can miss malignancy.

  • Experimental techniques for the development of a uterus transplantation model in cynomolgus macaques.

    Kisu I, Banno K, Obara H, Kato Y, Yamada Y, Matsubara K, Matoba Y, Emoto K, Masugi Y, Saiki Y, Ishigaki H, Itagaki I, Kawamoto I, Iwatani C, Nakagawa T, Murase M, Tsuchiya H, Nakagawa K, Shiina T, Aoki D.

    J Obstet Gynaecol Res (Journal of Obstetrics and Gynaecology Research)   2020.09

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  13418076

     View Summary

    © 2020 Japan Society of Obstetrics and Gynecology Uterus transplantation (UTx) is now a treatment for women with uterine factor infertility to have a child. However, UTx is still largely at the experimental stage, and many medical issues remain unsolved. Therefore, adequate studies in large animals including non-human primates are required for validation of these issues. UTx research, especially in non-human primates, can provide important information for its full establishment in humans due to the anatomical and physiological similarities between the two. We accumulated data from UTx studies using cynomolgus macaques since 2009 and established autologous and allogeneic UTx models which led to deliveries after performing the procedure. In this paper, we summarized key points to develop UTx models in cynomolgus macaques based on our experience. UTx models in non-human primates can surely contribute new and beneficial knowledge in this field and can be useful for the further development of UTx in humans.

  • Impact of the COVID-19 epidemic at a high-volume facility in gynecological oncology in Tokyo, Japan: a single-center experience.

    Nogami Y, Kobayashi Y, Tsuji K, Yokota M, Nakamura M, Yamagami W, Morisada T, Tominaga E, Banno K, Aoki D.

    Journal of Ovarian Resarch (Journal of ovarian research)  13 ( 1 ) 105 2020.09

    Research paper (scientific journal), Joint Work, Accepted

     View Summary

    BACKGROUND: The number of cases of novel coronavirus disease 2019 (COVID-19) in Japan have risen since the first case was reported on January 24, 2020, and 6225 infections have been reported as of June 30, 2020. On April 8, 2020, our hospital began screening patients via pre-admission reverse transcriptase-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and chest computed tomography (CT). Although no patients exhibited apparent pneumonia, treatment delay or changes in treatment plans were required for a few patients based on the results of screening tests. During an emerging infectious disease pandemic, the likelihood of being infected, as well as the disease itself, affects clinical decision making in several ways. We summarized and presented our experience. CASE PRESENTATION: After the introduction of pre-admission screening, RT-PCR and CT were performed in 200 and 76 patients, respectively, as of June 30, 2020. The treatment of five patients, including two patients with cervical cancer, two patients with ovarian tumors, and one patient with ovarian cancer, was affected by the results. Two asymptomatic RT-PCR-positive patients did not develop COVID-19, but their treatment was delayed until the confirmation of negative results. The other three patients were RT-PCR-negative, but abnormal CT findings suggested the possibility of COVID-19, which delayed treatment. The patients receiving first-line preoperative chemotherapy for ovarian cancer had clinically evident exacerbations because of the treatment delay. CONCLUSION: During the epidemic phase of an emerging infectious disease, we found that COVID-19 has several other effects besides its incidence. The postponing treatment was the most common, therefore, treatment of ovarian tumors and ovarian cancer was considered to be the most likely to be affected among gynecological diseases. Protocols that allow for easy over-diagnosis can be disadvantageous, mainly because of treatment delays, and therefore, the protocols must be developed in light of the local infection situation.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

display all >>

Reviews, Commentaries, etc. 【 Display / hide

display all >>

Presentations 【 Display / hide

  • コンパニオン診断としてMSI検査を行った婦人科癌症例の臨床病理・遺伝学的検討

    竹田 貴、小林佑介、永井晋平、辻 浩介、増田健太、西尾 浩、冨永英一郎、阪埜浩司、青木大輔

    第140回関東連合産科婦人科学会総会・学術講演会, 2020.11, Oral Presentation(general)

  • 女性のQOLを低下させる comon disease(月経困難症と慢性便秘症)に対する薬物治療の新展開

    阪埜浩司

    Web 配信 産婦人科学術講演会 (石川県金沢市 KKRホテル金沢) , 2020.11, Oral Presentation(guest/special)

  • 婦人科悪性腫瘍に対する傍大動脈リンパ節郭清後に生じる乳糜腹水についての検討

    家谷佳那、増田健太、山上 亘、小林佑介、仲村 勝、林 茂徳、森定 徹、岩田 卓、冨永英一郎、阪埜浩司、田中守、青木大輔

    第140回関東連合産科婦人科学会総会・学術講演会, 2020.11, Oral Presentation(general)

  • 子宮体癌再発症例における再発部位ごとの診断契機の検討

    高橋美央、山上 亘、平野卓朗、白石 悠、吉村拓馬、黒田由香、同前 愛、坂井健良、千代田達幸、小林佑介、阪埜浩司、青木大輔

    第58回日本癌治療学会学術集会 (京都府京都市 国立京都会館) , 2020.10, Oral Presentation(general)

  • 当院におけるMPA療法後の妊娠成績に関する検討

    吉村拓馬 、山上 亘、大石真希、平野卓朗 、坂井健良 、真壁 健 、千代田達幸、宮越 敬、阪埜浩司、進 伸幸、田中 守、青木大輔

    第58回日本癌治療学会学術集会 (京都府京都市 国立京都会館) , 2020.10, Oral Presentation(general)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • エピゲノム異常を標的とした子宮内膜癌の新たな診断・治療法の探索

    2016.04
    -
    2019.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 阪埜 浩司, Grant-in-Aid for Scientific Research (C), Principal Investigator

  • ラットにおける半導体レーザー手術装置に関する基礎的研究

    2009.12
    -
    Present

    Commissioned research

  • 子宮内膜症に関する創薬標的の探索および疾患モデルの構築

    2009.10
    -
    Present

    Joint research

Awards 【 Display / hide

  • 平成25年度 日本医師会医学研究奨励賞

    BANNO KOUJI, 2013.11

  • 平成24年度 日本産科婦人科学会学術奨励賞

    BANNO KOUJI, 2012.12, 子宮体癌におけるジェネティクスとエピジェネティクス 〜子宮内膜の発癌とDNAミスマッチ修復遺伝子異常との関連を中心に〜

  • 平成23年度 医学部Best Teacher Award

    BANNO KOUJI, 2012.07

    Type of Award: Keio commendation etc.

  • 平成22年度 医学部Best Teacher Award

    BANNO KOUJI, 2011.06

    Type of Award: Keio commendation etc.

  • 平成21年度 医学部 Best Teacher Award

    BANNO KOUJI, 2010.03

    Type of Award: Keio commendation etc.

display all >>

 

Courses Taught 【 Display / hide

  • LECTURE SERIES, GYNECOLOGY

    2020

  • LECTURE SERIES, GYNECOLOGY

    2019

  • 大学院修士講義

    2019, Major subject, Lecture, Within own faculty

Courses Previously Taught 【 Display / hide

  • 婦人科 臨床実習

    Keio University, 2015, Full academic year, Major subject, Seminar, Lecturer outside of Keio, 5h, 100people

  • 大学院特別講義 臨床腫瘍学

    Keio University, 2015, Full academic year, Major subject, Lecture, Within own faculty, 30people

    家族性腫瘍

  • 婦人科学

    Keio University, 2015, Spring Semester, Major subject, Lecture, Within own faculty, 100people

  • 婦人科学 臨床実習

    Keio University, 2014, Full academic year, Major subject, Laboratory work/practical work/exercise, Within own faculty

  • 大学院講義 臨床腫瘍学

    Keio University, 2014, Full academic year, Other, Lecture, Within own faculty

display all >>

Educational Activities and Special Notes 【 Display / hide

  • 大学院特別講義 臨床腫瘍学

    2015.11
    -
    Present

    , Special Affairs

  • 婦人科学

    2015.09
    -
    Present

    , Special Affairs

  • 婦人科臨床実習

    2015.05
    -
    2015.12

    , Special Affairs

 

Social Activities 【 Display / hide

  • 日本子宮移植研究会

    2014.03
    -
    Present
  • 日本学術会議

    2007.01
    -
    2008.04
  • 女性の健康基金

    2005
    -
    2006

Memberships in Academic Societies 【 Display / hide

  • 日本家族性腫瘍学会, 

    2009.01
    -
    Present
  • 日本医師会総合政策研究機構, 

    2007.01
    -
    2008.09
  • 日本癌治療学会, 

    2002
    -
    Present
  • 日本婦人科腫瘍学会, 

    2002
    -
    Present
  • 日本臨床細胞学会, 

    2002
    -
    Present

display all >>

Committee Experiences 【 Display / hide

  • 2020.09
    -
    2022.08

    査読委員, 日本婦人科腫瘍学会

  • 2020.07
    -
    2022.06

    ガイドライン委員, 日本遺伝性腫瘍学会

  • 2020.07
    -
    2022.06

    作業部会委員, 日本遺伝性腫瘍学会

  • 2014.03
    -
    Present

    Director, 日本子宮移植研究会

  • 2009.01
    -
    Present

    Board of Councillors, 日本家族性腫瘍学会

display all >>